Soluble RAGE in type 2 diabetes: Association with oxidative stress

Free Radical Biology and Medicine

Volumn 43, Issue 4, 2007, Pages 511-518

  Devangelio, Eleonora ^a   Santilli, Francesca ^a   Formoso, Gloria ^a   Ferroni, Patrizia ^b   Bucciarelli, Loredana ^c   Michetti, Noemi ^a   Clissa, Cristina ^a   Ciabattoni, Giovanni ^a   Consoli, Agostino ^a   Davì, Giovanni ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

ADMA; Oxidative stress; RAGE; Type 2 diabetes

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; INSULIN; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DIABETIC ANGIOPATHY; FEMALE; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ARGININE; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DINOPROST; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; OXIDATIVE STRESS; RECEPTORS, IMMUNOLOGIC;

EID: 34447331279     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.03.015     Document Type: Article

References (39)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414 (2001) 813-820
2. Schmidt A.M., Yan S.D., Wautier J.L., and Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ. Res. 84 (1999) 489-497
3. Schmidt A.M., Yan S.D., Yan S.F., and Stern D.M. The biology of receptor for advanced glycation end products and its ligands. Biochim. Biophys. Acta 1498 (2000) 99-111
4. Schmidt A.M., Hori O., Chen J.X., Li J.F., Crandall J., Zhang J., Cao R., Yan S.D., Brett J., and Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Invest. 96 (1995) 1395-1403
5. Schmidt A.M., Yan S.D., and Stern D.M. The dark side of glucose. Nat. Med. 1 (1995) 1002-1004
6. Hofmann M.A., Drury S., Fu C., Qu W., Taguchi A., Lu Y., Avila C., Kambham N., Bierhaus A., Nawroth P., Neurath M.F., Slattery T., Beach D., McClary J., Nagashima M., Morser J., Stern D., and Schmidt A.M. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97 (1999) 889-901
7. Cipollone F., Iezzi A., Fazia M., Zucchelli M., Pini B., Cuccurullo C., De Cesare D., De Blasis G., Muraro R., Bei R., Chiarelli F., Schmidt A.M., Cuccurullo F., and Mezzetti A. The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108 (2003) 1070-1077
8. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., Hori O., Stern D., and Schmidt A.M. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J. Clin. Invest. 97 (1996) 238-243
9. Hanford L.E., Enghild J.J., Valnickova Z., Petersen S.V., Schaefer L.M., Schaefer T.M., Reinhart T.A., and Oury T.D. Purification and characterization of mouse soluble receptor for advanced glycation end products (sRAGE). J. Biol. Chem. 279 (2004) 50019-50024
10. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., Stern D., and Schmidt A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4 (1998) 1025-1031
11. Kislinger T., Tanji N., Wendt T., Qu W., Lu Y., Ferran Jr. L.J., Taguchi A., Olson K., Bucciarelli L., Goova M., Hofmann M.A., Cataldegirmen G., D'Agati V., Pischetsrieder M., Stern D.M., and Schmidt A.M. Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 905-910
12. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., Goova M.T., Moser B., Kislinger T., Lee D.C., Kashyap Y., Stern D.M., and Schmidt A.M. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
13. Wendt T., Bucciarelli L., Qu W., Lu Y., Yan S.F., Stern D.M., and Schmidt A.M. Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes. Curr. Atheroscler. Rep. 24 (2002) 228-237
14. Yonekura H., Yamamoto Y., Sakurai S., Watanabe T., and Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci. 97 (2005) 305-311
15. Basta G., Schmidt A.M., and De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63 (2004) 582-592
16. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T., Sakamoto K., Nakatani Y., Ohtoshi K., Hayaishi-Okano R., Kosugi K., Hpri M., and Yamasaki Y. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients. Diabetes Care 28 (2005) 2716-2721
17. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., Emoto M., Shoji T., Tamei H., Matsuki H., Sakurai S., Yamamoto Y., Yonekura H., Watanabe T., Yamamoto H., and Nishizawa Y. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 2587-2593
18. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., Natali A., Ferrannini E., and Gastaldelli A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91 (2006) 4628-4634
19. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99 (1999) 224-229
20. Mukhopadhyay S., and Mukherjee T.K. Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective. Biochim. Biophys. Acta 1745 (2005) 145-155
21. Fliser D. Asymmetric dimethylarginine (ADMA): the silent transition from an 'uraemic toxin' to a global cardiovascular risk molecule. Eur. J. Clin. Invest. 35 (2005) 71-79
22. Wautier J.L., and Schmidt A.M. Protein glycation: a firm link to endothelial cell dysfunction. Circ. Res. 95 (2004) 233-238
23. Ramasamy R., Yan S.F., and Schmidt A.M. The RAGE axis and endothelial dysfunction: maladaptive roles in the diabetic vasculature and beyond. Trends Cardiovasc. Med. 15 (2005) 237-243
24. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20 (1997) 1183-1197
25. 2α is increased in hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 3230-3235
26. Schulze F., Wesemann R., Schwedhelm E., Sydow K., Albsmeier J., Cooke J.P., and Boger R.H. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin. Chem. Lab. Med. 42 (2004) 1377-1383
27. 2α excretion in man. J. Pharmacol. Exp. Ther. 5275 (1995) 94-100
28. Hudson B.I., Wendt T., Bucciarelli L.G., Rong L.L., Naka Y., Yan S.F., and Schmidt A.M. Diabetic vascular disease: it's all the RAGE. Antiox. Redox Signal. 7 (2005) 1588-1600
29. Hudson B.I., Harja E., Moser B., and Schmidt A.M. Soluble levels of receptor for advanced glycation endproducts (sRAGE) and coronary artery disease: the next C-reactive protein?. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 879-882
30. Lin K.Y., Ito A., Asagami T., Tsao P.S., Adimoolam S., Kimoto M., Tsuji H., Reaven G.M., and Cooke J.P. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine dimethylaminohydrolase. Circulation 106 (2002) 987-992
31. Xiong Y., Lei M., Fu S., and Fu Y. Effect of diabetic duration on serum concentrations of endogenous inhibitor of nitric oxide synthase in patients and rats with diabetes. Life Sci. 77 (2005) 149-159
32. Schulze F., Maas R., Freese R., Schwedhelm E., Silberhorn E., and Böger R.H. Determination of a reference value for NG, NG-dimethyl-L-arginine in 500 subjects. Eur. J. Clin. Invest. 35 (2005) 622-626
33. Krzyzanowska K., Mittermayer F., Krugluger W., Schnack C., Hofer M., Wolzt M., and Schernthaner G. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 189 (2006) 236-240
34. Schnabel R., Blankenberg S., Lubos E., Lackner K.J., Rupprecht H.J., Espinola-Klein C., Jachmann N., Post F., Peetz D., Bickel C., Cambien F., Tiret L., and Munzel T. Asymmetric dimethylarginine and risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 97 (2005) e53-e59
35. Asagami T., Abbasi F., Stuelinger M., Lamendola C., McLaughlin T., Cooke J.P., Reaven G.M., and Tsao P.S. Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism 51 (2002) 843-846
36. Cooke J.P. Asymmetrical dimethylarginine. The Über marker?. Circulation 109 (2004) 1813-1819
37. Koyama H., Shoji T., Fukumoto S., Shinohara K., Shoji T., Emoto M., Mori K., Tahara H., Ishimura E., Kakiya R., Tabata T., Yamamoto H., and Nishizawa Y. Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease. Arterioscler. Thromb. Vasc. Biol. 27 (2007) 147-153
38. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., and Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1032-1037
39. Renard C., Chappey O., Wautier M.P., Nagashima M., Lundh E., Morser J., Zhao L., Schmidt A.M., Scherrmann J.M., and Wautier J.L. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharmacol. 52 (1997) 54-62